Cargando…
Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
BACKGROUND AND AIMS: Heterogeneity exists among patients with atherosclerotic cardiovascular disease (ASCVD) with regard to the risk of recurrent events. Current guidelines have definitely refined the disease and we aimed to examine the practicability in Chinese population. METHODS: A cohort of 9944...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096217/ https://www.ncbi.nlm.nih.gov/pubmed/35574011 http://dx.doi.org/10.3389/fendo.2022.860698 |
_version_ | 1784705925503778816 |
---|---|
author | Li, Sha Liu, Hui-Hui Guo, Yuan-Lin Zhu, Cheng-Gang Wu, Na-Qiong Xu, Rui-Xia Dong, Qian Qian, Jie Dou, Ke-Fei Li, Jian-Jun |
author_facet | Li, Sha Liu, Hui-Hui Guo, Yuan-Lin Zhu, Cheng-Gang Wu, Na-Qiong Xu, Rui-Xia Dong, Qian Qian, Jie Dou, Ke-Fei Li, Jian-Jun |
author_sort | Li, Sha |
collection | PubMed |
description | BACKGROUND AND AIMS: Heterogeneity exists among patients with atherosclerotic cardiovascular disease (ASCVD) with regard to the risk of recurrent events. Current guidelines have definitely refined the disease and we aimed to examine the practicability in Chinese population. METHODS: A cohort of 9944 patients with ASCVD was recruited. Recurrent events occurred during an average of 38.5 months’ follow-up were collected. The respective and combinative roles of major ASCVD (mASCVD) events and high-risk conditions, being defined by 2018 AHA/ACC guideline, in coronary severity and outcome were studied. RESULTS: The number of high-risk conditions was increased with increasing number of mASCVD events (1.95 ± 1.08 vs. 2.16 ± 1.10 vs. 2.42 ± 1.22). Trends toward the higher to the highest frequency of multi-vessel coronary lesions were found in patients with 1- (71.1%) or ≥2 mASCVD events (82.8%) when compared to those without (67.9%) and in patients with 2- (70.5%) or ≥3 high-risk conditions (77.4%) when compared to those with 0-1 high-risk condition (61.9%). The survival rate was decreased by 6.2% between none- and ≥2 mASCVD events or by 3.5% between 0-1 and ≥3 high-risk conditions. Interestingly, diabetes was independently associated with outcome in patients with 1- [1.54(1.06-2.24)] and ≥2 mASCVD events [1.71(1.03-2.84)]. The positive predictive values were increased among groups with number of mASCVD event increasing (1.10 vs. 1.54 vs. 1.71). CONCLUSION: Propitious refinement of ASCVD might be reasonable to improve the survival. Concomitant diabetes was differently associated with the incremental risk among different ASCVD categories, suggesting the need of an appropriate estimate rather than a ‘blanket’ approach in risk stratification. |
format | Online Article Text |
id | pubmed-9096217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90962172022-05-13 Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease Li, Sha Liu, Hui-Hui Guo, Yuan-Lin Zhu, Cheng-Gang Wu, Na-Qiong Xu, Rui-Xia Dong, Qian Qian, Jie Dou, Ke-Fei Li, Jian-Jun Front Endocrinol (Lausanne) Endocrinology BACKGROUND AND AIMS: Heterogeneity exists among patients with atherosclerotic cardiovascular disease (ASCVD) with regard to the risk of recurrent events. Current guidelines have definitely refined the disease and we aimed to examine the practicability in Chinese population. METHODS: A cohort of 9944 patients with ASCVD was recruited. Recurrent events occurred during an average of 38.5 months’ follow-up were collected. The respective and combinative roles of major ASCVD (mASCVD) events and high-risk conditions, being defined by 2018 AHA/ACC guideline, in coronary severity and outcome were studied. RESULTS: The number of high-risk conditions was increased with increasing number of mASCVD events (1.95 ± 1.08 vs. 2.16 ± 1.10 vs. 2.42 ± 1.22). Trends toward the higher to the highest frequency of multi-vessel coronary lesions were found in patients with 1- (71.1%) or ≥2 mASCVD events (82.8%) when compared to those without (67.9%) and in patients with 2- (70.5%) or ≥3 high-risk conditions (77.4%) when compared to those with 0-1 high-risk condition (61.9%). The survival rate was decreased by 6.2% between none- and ≥2 mASCVD events or by 3.5% between 0-1 and ≥3 high-risk conditions. Interestingly, diabetes was independently associated with outcome in patients with 1- [1.54(1.06-2.24)] and ≥2 mASCVD events [1.71(1.03-2.84)]. The positive predictive values were increased among groups with number of mASCVD event increasing (1.10 vs. 1.54 vs. 1.71). CONCLUSION: Propitious refinement of ASCVD might be reasonable to improve the survival. Concomitant diabetes was differently associated with the incremental risk among different ASCVD categories, suggesting the need of an appropriate estimate rather than a ‘blanket’ approach in risk stratification. Frontiers Media S.A. 2022-04-28 /pmc/articles/PMC9096217/ /pubmed/35574011 http://dx.doi.org/10.3389/fendo.2022.860698 Text en Copyright © 2022 Li, Liu, Guo, Zhu, Wu, Xu, Dong, Qian, Dou and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Li, Sha Liu, Hui-Hui Guo, Yuan-Lin Zhu, Cheng-Gang Wu, Na-Qiong Xu, Rui-Xia Dong, Qian Qian, Jie Dou, Ke-Fei Li, Jian-Jun Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease |
title | Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease |
title_full | Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease |
title_fullStr | Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease |
title_full_unstemmed | Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease |
title_short | Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease |
title_sort | current guideline risk stratification and cardiovascular outcomes in chinese patients suffered from atherosclerotic cardiovascular disease |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096217/ https://www.ncbi.nlm.nih.gov/pubmed/35574011 http://dx.doi.org/10.3389/fendo.2022.860698 |
work_keys_str_mv | AT lisha currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease AT liuhuihui currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease AT guoyuanlin currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease AT zhuchenggang currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease AT wunaqiong currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease AT xuruixia currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease AT dongqian currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease AT qianjie currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease AT doukefei currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease AT lijianjun currentguidelineriskstratificationandcardiovascularoutcomesinchinesepatientssufferedfromatheroscleroticcardiovasculardisease |